Fortress Biotech, Inc.
FBIONASDAQHealthcare● Active
$2.85
+$0.20(+7.55%)
Market Cap$94674355
P/E Ratio—
52W High$4.53
52W Low$1.7
Fortress Biotech, Inc. (FBIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FBIO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
$2.82
Est. -$0.22 · +1381.8%
Revenue
$0.02B
Est. $0.02B · -1.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
FBIO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.20 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.22 | $2.82 | +1381.8% | $0.02B | $0.02B | -1.8% |
| ▼ Q1 FY2026 | Mar 31, 2026 | $0.42 | -$0.21 | -150.0% | $0.02B | $0.03B | -38.5% |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.43 | $0.11 | +125.6% | $0.02B | $0.02B | -16.1% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.31 | -$0.46 | -48.4% | $0.02B | $0.02B | -21.9% |
| ▼ Q2 FY2025 | May 21, 2025 | -$0.44 | -$1.03 | -134.1% | $0.01B | $0.01B | +13.1% |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.79 | -$0.53 | +32.9% | $0.02B | $0.02B | -7.2% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.27 | -$0.76 | -181.5% | $0.01B | $0.02B | -6.1% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
$2.82
EPS Est.
-$0.22
EPS Surpr.
+1381.8%
Revenue
$0.02B
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.21
EPS Est.
$0.42
EPS Surpr.
-150.0%
Revenue
$0.02B
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
$0.11
EPS Est.
-$0.43
EPS Surpr.
+125.6%
Revenue
$0.02B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.31
EPS Surpr.
-48.4%
Revenue
$0.02B
Q2 FY2025
May 21, 2025Miss
EPS Actual
-$1.03
EPS Est.
-$0.44
EPS Surpr.
-134.1%
Revenue
$0.01B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.79
EPS Surpr.
+32.9%
Revenue
$0.02B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.76
EPS Est.
-$0.27
EPS Surpr.
-181.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q2 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q1 FY2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q4 FY2025 | $0.11 | $0.11 | $0.11 | 1 |
| Q3 FY2025 | $-0.42 | $-0.42 | $-0.42 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +1381.8% | $2.23 | $2.30 | +3.14% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -150.0% | $2.70 | $2.79 | +3.33% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +125.6% | $2.49 | $2.62 | +5.22% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -48.4% | $1.93 | $1.96 | +1.55% |
| ▼ Q2 FY2025 | May 21, 2025 | -134.1% | $1.75 | $1.70 | -2.86% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +32.9% | $1.68 | $1.73 | +2.98% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -181.5% | $1.65 | $1.57 | -4.85% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +44.7% | $1.77 | $1.83 | +3.39% |
Q2 FY2026+3.14%
Report Date
May 14, 2026
EPS Beat/Miss
+1381.8%
Price Before
$2.23
Price After
$2.30
Q1 FY2026+3.33%
Report Date
Mar 31, 2026
EPS Beat/Miss
-150.0%
Price Before
$2.70
Price After
$2.79
Q4 FY2025+5.22%
Report Date
Nov 14, 2025
EPS Beat/Miss
+125.6%
Price Before
$2.49
Price After
$2.62
Q3 FY2025+1.55%
Report Date
Aug 14, 2025
EPS Beat/Miss
-48.4%
Price Before
$1.93
Price After
$1.96
Q2 FY2025-2.86%
Report Date
May 21, 2025
EPS Beat/Miss
-134.1%
Price Before
$1.75
Price After
$1.70
Q1 FY2025+2.98%
Report Date
Mar 27, 2025
EPS Beat/Miss
+32.9%
Price Before
$1.68
Price After
$1.73
Q4 FY2024-4.85%
Report Date
Nov 14, 2024
EPS Beat/Miss
-181.5%
Price Before
$1.65
Price After
$1.57
Q3 FY2024+3.39%
Report Date
Aug 13, 2024
EPS Beat/Miss
+44.7%
Price Before
$1.77
Price After
$1.83
Avg Beat Reaction+3.68%
Avg Miss Reaction-0.71%
Beat Rate4 / 8 quarters
Largest Move+5.22% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FBIO ends December
Fortress Biotech, Inc. (FBIO) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $2.82 — beating the analyst consensus of $-0.22 by +1381.8%. The next FBIO earnings date is expected around September 1, 2026.
Each quarter, investors track FBIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FBIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FBIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FBIO earnings · 5 questionsFortress Biotech, Inc.'s next earnings report is expected around September 1, 2026. FBIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FBIO historically reports after market close (AMC).
FBIO earnings datewhen is FBIO earningsFBIO next earnings datewhen does FBIO report earningsFBIO earnings calendar
▸ Source: FMP · Fortress Biotech, Inc. SEC filings · US GAAP · Fortress Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026